SET OF OLIGODEOXYRIBONUCLEOTIDE PRIMERS AND FLUORESCENTLY LABELED DNA PROBES FOR DETERMINING THE EXPRESSION OF THE SOCS2, CD34, FAM30A, GPR56, DNMT3B, SPINK2 GENES, FOLLOWED BY DETERMINING THE LEVEL OF RELATIVE EXPRESSION RELATIVE TO THE ABL1 REFERENCE GENE, AMPLIFIED IN REAL-TIME PCR, USED TO PREDICT THE RISK OF EARLY RELAPSE IN CHILDREN WITH ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Russian patent published in 2022 - IPC C12Q1/68 

FIELD: biotechnology and medicine.

SUBSTANCE: invention relates to biotechnology and medicine, namely to oncohematology for predicting the risk of recurrence of acute myeloid leukemia in children after allogeneic transplantation of hematopoietic stem cells. A set of oligodeoxyribonucleotide primers and fluorescently labeled DNA probes is developed to determine the expression of the CD34, FAM30A, SOCS2, GPR56, DNMT3B, SPINK2 genes, followed by determination of the level of relative expression relative to the ABL1 reference gene. Together, the level of expression of the above genes can be used as a predictor of the development of early recurrence of AML in children after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

EFFECT: invention can be used to detect the level of expression of genes characteristic of leukemic stem cells (LSCs) of acute myeloid leukemia (AML) in children by real-time polymerase chain reaction (RT-PCR) before allogeneic bone marrow transplantation in order to predict the risk of early post-transplant recurrence.

1 cl, 1 tbl, 1 dwg